Sebela Women's Health Inc, part of US pharmaceutical company Sebela Pharmaceuticals, announced on Wednesday that its MIUDELLA Hormone-Free Copper Intrauterine System (IUS) has been named to TIME's list of the best inventions of 2025.
Sebela says that MIUDELLA is the first hormone-free copper intrauterine device (IUD) in the US in over 40 years. It was approved by the US Food and Drug Administration in February 2025 for the prevention of pregnancy in females of reproductive potential for up to three years, and it is expected to be available to patients through trained healthcare providers in the US in the first half of 2026.
To compile this year's list, TIME solicited nominations from TIME editors and correspondents around the world through an online application process, paying special attention to growing fields -- such as health care and AI. It then evaluated each contender on several key factors, including originality, efficacy, ambition, and impact.
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Novocure announces presentation of new TTFields research at EANO and ESMO 2025 meetings
OSR Holdings to acquire Korean non-invasive glucose monitor developer Woori IO
Autonomix Medical secures new US patent to expand precision nerve-targeted therapies
MedHub-AI's AutocathFFR receives national reimbursement approval in Japan
Microbot Medical secures first Japanese patent for Liberty robotic system following FDA clearance
Polarean Imaging signs new supply agreementwith UVA Health for clinical Xenon MRI
Femasys partners with Kebomed to expand FemBloc permanent birth control in France and Benelux
Implantica receives positive FDA feedback on final RefluxStop PMA submission
Tempus secures FDA clearance for RNA-based xR IVD diagnostic device
Shoulder Innovations expands I-Series portfolio with launch of InSet 70 Humeral Stem
GSK commits USD30bn to US R&D and manufacturing expansion
ArtPlayer Promotes Elderly Wellbeing with Digital Signage and Streaming Art in Finnish Care Homes